FDA Declines to Approve Epinephrine Nasal-Spray, Asks for Additional Data
Wall Street Journal
Shares of ARS Pharmaceuticals sank 50% premarket.
Understanding current events through the lenses of the past and future.
Wall Street Journal
Shares of ARS Pharmaceuticals sank 50% premarket.